In accordance to the trials conducted in North America, Rimonabant has proved effective in treatment of obesity. The results of metabolic and weight-control in  Phase 3 study over 2 years in over 3000 patients with Rimonabant, demonstrate that benefits achieved with a 20-mg daily dosage of Rimonabant. Rimonabant in Obesity trial conducted in North America (RIO-NA) was the biggest clinical trial of Rimonabant till date. Rimonabant in Obesity or Overweight (RIO) involves over 6600 participants.

Rimonabant in Obesity was conducted in the US and Canada. The recently proclaimed 2-year results are consistent with those already reported clinical trials with Rimonabant in overweight or obese patients: those with untreated dyslipidemia (RIO-Lipids) and even those with or without comorbidities (RIO-Europe). Both of these clinical trials displayed noteworthy weight loss, with optimistic effects on lipid and glycemic profiles.

Fixed-dose routines of 5mg and 20mg Rimonabant once daily with placebo over a period of 2 years have proven. After a week of screening period, patients were approved a mild hypocaloric diet which was designed to reduce daily caloric intake by 600 kcal and went into a 4-week, single-blind, placebo disagreement period. Randomly patients were allocated to 1 of the 3 groups of treatment: placebo or Rimonabant 5 mg or 20 mg for 52 weeks of double-blind treatment.
 
Subsequent to the first year of treatment, patients on Rimonabant 5 mg or 20 mg were re-randomized either to carry on the same dosage of Rimonabant or change to placebo, employing a randomization ratio of 1:1 for an added 52-week treatment period. The placebo group continued on placebo throughout the second year. A measure of abdominal fat, waist circumference was also significantly condensed.

Buy Acomplia for Europe only € 142.55

Buy Acomlia for USA only $245.00

While diabetic patients were not incorporated in the study, patients on Rimonabant 20 mg had considerably improved insulin sensitivity in comparison to Rimonabant 5 mg and on placebo. To some extent higher incidences of anxiety, depression, and irritability were stated in the Rimonabant 20-mg treatment group comparison to the placebo group.

Rimonabant was also conducted universally in the diabetic patients (RIO-Diabetes) and as a support to smoking cessation in the STRATUS (Studies with Rimonabant and Tobacco Use) Program which have proven to be positive.